The Alarming Rise of Colorectal Cancer in Young Adults

Colorectal cancer has become the leading cause of cancer-related death for individuals under 50 in the United States — a trend also observed across multiple other high-income nations.

Incidence and mortality rates are rising among adults in their 20s, 30s, and 40s, while declining in older populations. Research into the causes points to a likely combination of environmental, dietary, and lifestyle factors, but no single cause has been identified. In response, screening guidelines in the U.S. have been updated to include new testing options and a lower recommended starting age.

Rising Incidence and Mortality

Global and National Trends

Multiple studies have documented a sustained increase in colorectal cancer cases among younger populations.

An analysis of over 96,400 cases in Switzerland between 1980 and 2021 found that incidence among individuals under 50 increased at approximately 0.5% annually, reaching 7 cases per 100,000 person-years. Cancers in this age group accounted for 6.1% of all colorectal cancer cases in the country. During the same period, incidence rates declined by 1.7% for men and 2.8% for women in the 50–74 age group.

In Germany, a study of more than 28,000 cases from 2003 to 2023 found a slight increase in incidence for adults aged 20–39, with rates for those aged 40–49 remaining stable. The authors noted that colorectal cancer before age 50 remains rare in Germany, representing about 5% of the roughly 56,000 new annual cases.

In the United States, data from the American Cancer Society shows that colorectal cancer incidence in adults under 50 has been increasing since the early 2000s. The disease is now the leading cause of cancer death in this age group. Colorectal cancer mortality in Americans under 50 increased by 1.1% annually since 2005. Adults aged 65 and younger now account for 45% of all new colorectal cancer cases, a significant increase from 27% in 1995.

Rectal Cancer Increases

A study presented at Digestive Disease Week 2026 reported that rectal cancer mortality among adults aged 20–44 is increasing at a rate two to three times faster than colon cancer mortality. The research, which analyzed CDC death records from 1999 to 2023, found that this mortality gap is widening across all demographic groups studied. For older millennials (ages 35–44), rectal cancer mortality is projected to rise through 2035. The Swiss study also found that the increase in incidence primarily concerned rectal cancers in both sexes and right-sided colon cancers in young women. Rectal cancers now account for approximately 32% of all colorectal cancer diagnoses in the U.S.

Stage at Diagnosis

Younger patients are more likely to be diagnosed at advanced stages.

In the Swiss study, approximately 28% of patients under 50 presented with metastatic disease at diagnosis, compared to about 20% of older patients. The American Cancer Society reports that 60% of colorectal cancer patients under 50 are diagnosed at stage 3 or 4, and 75% of people under 50 are diagnosed with advanced disease. One study indicated that younger patients with metastatic colon cancer may have a slightly lower survival rate than patients aged 50 or older.

Sociodemographic Disparities

A study published in JAMA Oncology analyzed more than 101,000 colorectal cancer deaths among adults aged 25–49 in the U.S. from 1994 to 2023. The overall death rate in this age group rose from approximately 3 to 4 per 100,000. The increase occurred almost entirely among individuals without a four-year college degree.

Among those with only a high school education, the death rate rose from 4 to 5.2 per 100,000. For individuals with at least a bachelor's degree, the rate remained unchanged at 2.7 per 100,000.

Researchers noted that education level serves as a proxy for socioeconomic factors because death certificates document educational attainment but not income, health insurance status, or lifestyle factors. Experts noted that people without college degrees tend to have lower incomes, poorer diets, less physical activity, and less access to medical care.

Hispanic adults and residents of Western states experienced the largest increases in rectal cancer deaths in the U.S., according to the Digestive Disease Week 2026 study.

Potential Causes and Risk Factors

Established Risk Factors

The following factors are recognized as increasing the risk of colorectal cancer:

• Family history of colorectal cancer or polyps
• Genetic conditions including Lynch syndrome, Familial Adenomatous Polyposis (FAP), and other hereditary syndromes
• Inflammatory bowel disease such as chronic ulcerative colitis and Crohn's disease
• Obesity
• Smoking
• Heavy alcohol consumption
• A diet high in red and processed meats and low in fruits, vegetables, and fiber
• Physical inactivity

Factors Under Investigation

Researchers have not identified a single cause for the rise in cases among younger populations. The following factors are being investigated as potential contributors:

Gut microbiome: Disruption of the gut microbiome, or dysbiosis, is considered a potential factor. A study published in Nature found that DNA mutations caused by colibactin, a toxin produced by certain strains of E. coli, were more common in younger colorectal cancer patients than in older ones.

Dietary changes: Increased consumption of ultra-processed foods and changes in dietary patterns have been correlated with early-onset disease. Researchers suggest that dietary changes introduced in the latter half of the 20th century may be relevant.

Environmental exposures: Microplastics, chemicals in plastics and detergents, and other environmental factors are under investigation. Cancer epidemiologist Rebecca Siegel described the trend as a "birth cohort effect," suggesting an exposure or risk factor that increased risk with each subsequent generation.

Antibiotic use: Repeated antibiotic use has been suggested as a potential association with early-onset colorectal cancer.

Alcohol consumption: The International Agency for Research on Cancer (IARC) classifies alcoholic beverages as a Group 1 carcinogen. Alcohol metabolizes into acetaldehyde, which can damage cellular DNA. The relationship between alcohol and colorectal cancer risk is dose-dependent; moderate consumption of at least two drinks per day can increase lifetime risk by at least 25%.

Screening effects: Some researchers noted that part of the observed increase in incidence may be due to earlier and improved diagnosis, as there has been an increase in tumors detected at an early stage with a comparatively favorable prognosis.

Symptoms and Diagnosis

Common Symptoms

Multiple sources identify the following symptoms as potential indicators of colorectal cancer:

• Blood in the stool or rectal bleeding (described as a primary indicator)
• Changes in bowel habits, such as diarrhea, constipation, or narrowing of stool, persisting for more than a few days
• Persistent abdominal pain or cramping, often on the left side
• Unintended weight loss
• Unexplained fatigue or weakness
• Iron deficiency anemia, which can result from slow blood loss
• A lingering sensation of needing a bowel movement even after passing stool
• Pencil-thin stools

Diagnostic Delays

Younger patients experience longer delays in diagnosis.

One study found an average seven-month delay between symptom onset and treatment for younger patients, compared to one month for older adults. This is partly because symptoms such as rectal bleeding or changes in bowel habits are often initially attributed to benign conditions like hemorrhoids, and because both patients and healthcare providers may not initially suspect colorectal cancer in younger individuals.

Screening Recommendations

Current Guidelines

The American Cancer Society (ACS) and the U.S. Preventive Services Task Force (USPSTF) recommend that average-risk individuals begin colorectal cancer screening at age 45. The ACS lowered its recommended starting age from 50 in 2018, with subsequent adoption by the USPSTF in 2021. Screening is recommended to continue through age 75 for those with a life expectancy over 10 years. Screening is discouraged after age 85.

The risk of colorectal cancer for individuals aged 40–44 is approximately 21 per 100,000 people. This risk more than doubles to 47 per 100,000 for those aged 45–49.

Screening Methods

Colonoscopy is widely described as the gold standard for screening. It allows direct visualization of the colon and rectum and can detect and remove precancerous polyps during the procedure. For average-risk individuals, a colonoscopy is recommended every 10 years.

Stool-based tests include:

• Fecal immunochemical tests (FIT), recommended annually
• High-sensitivity fecal occult blood tests (gFOBT), recommended annually
• Multi-target stool DNA tests (including Cologuard, Cologuard Plus, and ColoSense), recommended every three years

Blood-based tests were added to the ACS guidelines in 2026. The Shield test, developed by Guardant Health and approved by the FDA in 2024, is the first blood-based test included. It detects DNA fragments from cancerous tumors with 83% sensitivity for colorectal cancer and 90% specificity. It is less effective at detecting precancerous polyps, with 13.2% sensitivity for advanced precancerous lesions. The test is recommended only for individuals who decline or do not complete other screening methods. Blood-based tests are recommended every three years.

Visual exams include virtual colonoscopy (CT colonography) every five years and flexible sigmoidoscopy every five years.

Screening for Higher-Risk Individuals

Individuals with a family history of colorectal cancer should begin screening earlier. Screening is generally recommended at age 40, or 10 years prior to the age of the youngest affected relative's diagnosis, whichever comes first, with repeat colonoscopies every five years. Individuals with genetic conditions such as Lynch syndrome may begin colonoscopies at age 20–25. Those with Familial Adenomatous Polyposis (FAP) may begin annual screenings as early as age 10–12. Individuals with inflammatory bowel disease may also be advised to begin screening before age 45.

Screening Uptake

Only 37% of adults aged 45–49 were up to date with colorectal cancer screening in 2023.

This compares to 55% for those aged 50–54. Approximately one-third of eligible adults overall have not been screened. Half of colorectal cancer deaths in people under 50 occur in the 45–49 age group, suggesting that many deaths in this cohort are potentially preventable through screening.

Insurance and Cost Coverage

Insurance coverage for preventive screening typically starts at age 45. Under the Affordable Care Act, recommended screening tests for average-risk patients are generally covered without cost-sharing. However, colonoscopies performed due to symptoms may be classified as diagnostic tests, which can involve deductibles or co-pays. For individuals under 45 with symptoms or family history, diagnostic tests must be requested and may involve out-of-pocket costs.

• Shield blood test: Medicare-covered with no copay for most beneficiaries; list price approximately $1,495
• Cologuard Plus and ColoSense: Typically covered by insurance; out-of-pocket cost for uninsured approximately $650
• Colonoscopy: Generally fully covered for preventive screening; out-of-pocket cost without insurance ranges from $1,250 to over $4,000

Prevention Strategies

Lifestyle Modifications

Researchers and medical organizations recommend the following measures to reduce colorectal cancer risk:

• Maintaining a healthy weight
• Engaging in regular physical activity (150 minutes per week)
• Adopting a diet rich in fruits, vegetables, and fiber, and low in processed meats and red meat
• Limiting or eliminating alcohol consumption
• Not using tobacco products
• Limiting consumption of sugar-sweetened beverages

A study demonstrated that a three-year exercise program improved survival rates and reduced recurrence in colon cancer patients.

Patient Experiences

Multiple individuals have shared their diagnoses and treatment experiences to raise awareness:

A 41-year-old Texas woman was diagnosed with Stage II rectal cancer in 2025 after experiencing blood in her stool and changes in bowel movements, which she attributed to diet changes. She began chemotherapy and is scheduled for further testing to determine subsequent treatment.

A 39-year-old woman was diagnosed with stage 4 colon cancer at age 31 after experiencing persistent abdominal pain during and after pregnancy. Her condition is stable after years of treatment, but she requires indefinite therapy due to previous recurrences.

A 20-year-old college student was diagnosed with stage 2 colon cancer after experiencing stomach pain over three months. She completed chemotherapy and is currently cancer-free, undergoing quarterly blood tests and annual colonoscopies.

A 33-year-old woman was diagnosed with stage 4 colon cancer with liver and lung metastases. She undergoes chemotherapy every other week and continues to receive treatment.

A 31-year-old man was diagnosed with colorectal cancer without knowing his family history of the disease. He is currently cancer-free.

A 42-year-old man was diagnosed with stage 3 colon cancer that has since progressed to stage 4. He reported no family history of colorectal cancer.

Recent Developments

American Cancer Society Screening Guideline Update (2026)

The ACS updated its colorectal cancer screening guidelines to include:

• Blood-based tests (specifically the Shield test by Guardant Health) as an option for adults aged 45 and older who decline or do not complete other screening methods
• Two new stool-based tests: Cologuard Plus and ColoSense, recommended every three years
• Blood-based tests recommended every three years

The ACS guidelines noted that blood tests are not the preferred option for screening. Colonoscopy remains the most effective method for detecting and removing precancerous polyps.

JAMA Oncology Study on Education and Mortality (2024)

A study published in JAMA Oncology found that the increase in colorectal cancer deaths among younger adults over the past 30 years occurred almost entirely among individuals without a four-year college degree. Researchers analyzed 101,000 deaths in adults aged 25–49. The findings were based on death certificate data, which includes education level but not other socioeconomic factors.

German Cancer Registry Study (2023)

A study published in the International Journal of Cancer analyzed 28,000 cases of colorectal cancer in Germany and found a slight increase in incidence among adults aged 20–39 from 2003 to 2023. Rates among those aged 40–49 remained stable. The authors did not recommend lowering the general screening age below 50 in Germany, noting that colorectal cancer before age 50 remains rare in that country.

Swiss National Study (2023)

A study published in the European Journal of Cancer analyzed 96,410 colorectal cancer cases in Switzerland from 1980 to 2021. The study found increasing incidence among those under 50 and declining rates in the 50–74 age group. The increase primarily concerned rectal cancers and right-sided colon cancers in young women.